Disc Medicine Reports $55.2 Million Net Loss in Q2 2025, Driven by Increased R&D Expenses

Disc Medicine, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2025. The company recorded a net loss of $55.2 million for the quarter, compared to a loss of $26.4 million in the same period last year, marking an increase of 109% year-over-year. For the first half of 2025, the net loss was $89.3 million, up from $53.3 million in the first half of 2024. The increase in losses is attributed primarily to heightened research and development expenses, which surged to $46.3 million in Q2 2025 from $23.5 million in Q2 2024, driven largely by costs associated with the ongoing APOLLO clinical trial for its lead product candidate, bitopertin.

The company’s total operating expenses for the second quarter of 2025 reached $61.4 million, a substantial increase from $30.9 million in the same quarter of the previous year. This rise reflects not only the increased R&D spending but also a rise in selling, general, and administrative expenses, which grew to $15.1 million from $7.4 million year-over-year. The company has not yet generated any revenue from product sales, as it remains in the clinical development stage, focusing on treatments for hematologic diseases.

In terms of strategic developments, Disc Medicine has made notable progress in its clinical trials. The company initiated the APOLLO trial in May 2025, which is designed to support a potential New Drug Application (NDA) for bitopertin under the FDA’s Accelerated Approval Program. Additionally, the company has entered into various licensing agreements, including a significant collaboration with AbbVie and a recent acquisition of a privately held company focused on myelodysplastic syndromes. As of June 30, 2025, Disc Medicine had cash, cash equivalents, and marketable securities totaling $650 million, which the company believes will be sufficient to fund its operations into 2028.

Operationally, Disc Medicine has expanded its workforce to support its growing clinical programs, with personnel-related costs increasing significantly. The company’s employee headcount has risen, contributing to higher stock-based compensation expenses. The company is also actively engaged in multiple clinical trials for its product candidates, including DISC-0974 and DISC-3405, which are in various stages of development. The company’s strategic focus on hematologic diseases positions it within a rapidly evolving market, although it faces substantial competition and regulatory hurdles.

Looking ahead, Disc Medicine anticipates continued operating losses as it advances its clinical programs. The company has indicated that it may require additional funding to support its operations and product development efforts. The management remains optimistic about the potential for its product candidates to achieve regulatory approval and generate revenue in the future, although the timeline for commercialization remains uncertain. The company is committed to addressing its material weaknesses in internal controls, which were identified in its financial reporting, and is implementing measures to enhance its operational effectiveness.